Tri-Institutional Tuberculosis Research Advancement Center (TRAC)

总体摘要：我们建议成立一个三机构结核病研究促进中心。 (TRAC)在威尔康奈尔医学院、纪念斯隆-凯特琳癌症中心和洛克菲勒大学。这个 在纽约市的一个三位一体(Tri-I)校园里，三所学校毗邻而立。目的 拟议的Tri-I TRAC的其中一个目的是汇集一个由20名高级结核病患者组成的优秀团队的专业知识和资源 这三个机构的调查人员将扩大结核病研究领域的调查人员人数，并 推动创新的多学科结核病研究。高级调查员拥有不同的专业知识。 横跨生物化学、基础微生物学、分枝杆菌遗传学、人类遗传学和免疫学、药物 发现、国际临床试验和实施科学。主要的重点将是支持新的 调查人员(NIS)，我们将他们定义为高级博士后研究员或初级教员，他们寻求 学术生涯，还没有拿到R01。我们还将招募新的结核病(N2TB)调查人员， 他们是其他科学学科的R01经验丰富的研究人员，他们将自己的专业知识带到结核病研究中。这个 Trac将有四个核心。行政核心将提供领导、财务监督、 沟通，以及项目评估。发展核心将资助6个发展项目奖 每年每人50,000美元，用于支持国家情报局和N2TB调查人员。来自威尔·康奈尔大学的机构支持 医学部将每年资助其中两个奖项，这些奖项将被指定给代表人数不足的少数族裔。 和女科学家。临床核心将建立在长期合作的基础上，主要在海地和 也是在坦桑尼亚。基础和临床科学核心将为发展中的NI和N2TB接受者提供 项目奖：结核病研究独有的导师、技术专长和科学资源，包括 获取结核病动物模型、转基因分枝杆菌文库和生物库临床样本。这个 基础和临床科学核心还将促进老年结核病之间的技术和资源共享 研究人员，以便启动新的合作转化型结核病研究路线。其他活动包括 一年一度的研讨会、技术研讨会和前往国际结核病临床地点的旅行将支持 建立新的结核病调查人员渠道，创造一个有利于多学科合作的环境。 与NIH的其他研究拨款、中心或机构核心不会有重叠。TRAC将利用 这些现有的资源和协同作用，扩大了结核病调查人员的数量，并培育了新的创新 合作的路线。我们的目标是在5年内让25家NIS成功竞争与结核病相关的NIH R01 并向独立过渡，并吸引至少5名N2TB研究人员从事结核病科学。一半将会是 女性和至少20%的少数族裔代表不足。我们还将启动新的协作产品线 旨在解决NIAID在结核病科学中的五个优先事项的转化研究，最终目标是改善结核病 诊断、预防和治疗以及消除世界范围内结核病的发病率和死亡率。

Overall Abstract: We propose a Tri-Institutional Tuberculosis (TB) Research Advancement Center (TRAC) at Weill Cornell Medicine, Memorial Sloan-Kettering Cancer Center and Rockefeller University. The three institutions are adjacent to each other on a Tri-Institutional (Tri-I) campus in New York City. The purpose of the proposed Tri-I TRAC is to pool the expertise and resources of an outstanding team of 20 senior TB investigators at the three institutions to expand the number of investigators in the field of TB research and to promote innovative multidisciplinary TB research. The senior investigators have diverse expertise spanning biochemistry, basic microbiology, mycobacterial genetics, human genetics and immunology, drug discovery, international clinical trials, and implementation science. A major focus will be supporting New Investigators (NIs), who we define as senior post-doctoral fellows or junior faculty members who seek an academic career and have not yet received an R01. We also will recruit New to TB (N2TB) Investigators, who are R01 experienced investigators in other scientific disciplines who bring their expertise to study TB. The TRAC will have four Cores. The Administrative Core will provide leadership, financial oversight, communication, and program evaluation. A Developmental Core will fund 6 Developmental Project Awards annually of $50,000 each to support NIs and N2TB investigators. Institutional support from Weill Cornell Medicine will fund two of these awards each year which will be designated for under-represented minorities and women scientists. The Clinical Core will build upon long-standing collaborations primarily in Haiti and also in Tanzania. The Basic and Clinical Science Cores will provide NI and N2TB recipients of Developmental Project Awards mentorship, technical expertise, and scientific resources unique to TB research including access to TB animal models, genetically modified mycobacterial libraries, and biobanked clinical samples. The Basic and Clinical Science Cores will also facilitate sharing of technology and resources between senior TB investigators in order to initiate new lines of collaborative translational TB research. Other activities including an annual symposium, a technology workshop, and travel to international TB clinical sites will bolster the pipeline of new TB investigators and generate an environment conducive to multidisciplinary collaboration. There will be no overlap with other NIH research grants, centers, or institutional cores. The TRAC will leverage these existing resources and synergistically expand the number of TB investigators and foster new innovative lines of collaboration. Our goal over 5 years is to have 25 NIs successfully compete for a TB related NIH R01 and transition to independence and to attract at least 5 N2TB investigators to TB science. Half will be women and at least 20% underrepresented minorities. We will also initiate new lines of collaborative translational research to address the five NIAID priorities in TB science with the ultimate goal of improving TB diagnostics, prevention, and treatment and ending morbidity and mortality from TB world-wide.